HEATHER LEMASTER: Open Payments
NPI 1508567363 · LEXINGTON, KY. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,909 in 106 payments from 24 companies in 2025. Trend: 2023 $669 · 2024 $1,044 · 2025 $1,909
Food & beverage: $1,902Education: $8
| Company | Payments | Amount |
|---|---|---|
| Vanda Pharmaceuticals Inc. | 14 | $412 |
| ABBVIE INC. | 18 | $256 |
| Supernus Pharmaceuticals, Inc. | 18 | $190 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 10 | $164 |
| AstraZeneca Pharmaceuticals LP | 5 | $107 |
| Teva Pharmaceuticals USA, Inc. | 5 | $99 |
| Bayer Healthcare Pharmaceuticals Inc. | 5 | $81 |
| Axsome Therapeutics, Inc. | 3 | $79 |
| Lilly USA, LLC | 4 | $66 |
| Janssen Pharmaceuticals, Inc | 2 | $61 |
Products named: VRAYLAR, HETLIOZ, Qelbree, FANAPT, CAPLYTA, FARXIGA, Kerendia, Auvelity.
Industry payments across KY — which companies pay providers there.
